Review Article

Could a Personalized Strategy Using Accelerated Partial Breast Irradiation be an Advantage for Elderly Patients? A Systematic Review of the Literature and Multidisciplinary Opinion

Luca Tagliaferri,1 Valentina Lancellotta,1 Giuseppe Colloca,1 Fabio Marazzi,1 Valeria Masiello,1 Giorgia Garganese,2,3 György Kovács,4 Vincenzo Valentini,1,5 and Maria Antonietta Gambacorta1,5

1UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione PoliChnico Universitario A. Gemelli IRCCS, Rome, Italy
2Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione PoliChnico Universitario A. Gemelli IRCCS, Rome, Italy
3Mater Olbia Hospital, Gynecology and Breast Care Center, Olbia, Italy
4Gemelli Interacts, Università Cattolica del Sacro Cuore, Rome, Italy
5Università Cattolica del Sacro Cuore, Istituto di Radiologia, Rome, Italy

Correspondence should be addressed to Valentina Lancellotta; valentina.lancellotta@policlinicogemelli.it

Received 15 August 2019; Accepted 27 November 2019; Published 28 February 2020

Academic Editor: Bruno Vincenzi

Copyright © 2020 Luca Tagliaferri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Elderly patients are underrepresented from a majority of clinical trials and the choice of the best treatment becomes a challenge. The optimal treatment should be personalized and based on a multidisciplinary approach that includes radiation oncologists, surgeons, geriatricians, medical oncologists, social workers, and support services. The global evaluation of the patients and the creation of nomograms may facilitate the definition of long-term treatment benefits minimizing the use of unnecessary therapy. Material and Method. A systematic research using PubMed, Scopus, and Cochrane library was performed to identify full articles analyzing the efficacy of APBI in elderly patients with breast cancer. ClinicalTrials.gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. Results. Seven papers fulfilled the eligibility criteria. The number of evaluated patients was 405 and the median age was 77.7 years. The disease-free survival (DFS) range was 96.1%–100%, the grade 3-4 toxicity range was 0%–6.6%, the cancer-specific survival (CSS) range was 97.9%–100%, and the overall survival (OS) range was 87%–100%. All studies reported excellent/good cosmetic results in a range of 74% to 99%. Conclusion. Accelerated partial breast irradiation (APBI) results in a safe and effective substitute for the adjuvant external beam radiotherapy in selected elderly early-stage breast cancer patients. Based on the relatively low toxicity, APBI should be advised in selected patients with life expectancies larger than 5–10 years.

1. Introduction

Breast cancer is the most common cancer in women, and the risk to develop breast cancer increases with age. Indeed 21% of all cases and 13% of breast cancer mortality occur in patients aged ≥70 years old [1]. Despite this data, elderly patients are underrepresented from a majority of clinical trials and the choice of the best treatment becomes a challenge. A great need remains for studies providing evidence levels to guide the treatment of elderly patients, which is often not guideline adherent. Patients aged 70 years and over, who are in good health condition, have a median life expectancy of 15.5 years and half of them will live much longer. Treatment decisions should not be based on age alone but need to ensure that older patients get the best quality of care [2, 3]. There is growing awareness that
functional age is a more accurate indicator of cancer treatment compliance because it differs between patients with the same chronologic age [4, 5]. Furthermore, consensus guidelines and position statements recommend the use of the geriatric assessment in elderly patients with cancer [6, 7] in order to avoid worsening of global quality of life.

The optimal treatment should be personalized [8–11] and based on a multidisciplinary approach that includes radiation oncologists, surgeons, geriatricians, medical oncologists, social workers, and support services. In this way, we can obtain an informed discussion of the estimated benefits and risks of cancer treatment. The global evaluation of the patients and the creation of nomograms [12, 13] may facilitate the definition of long-term treatment benefits minimizing the use of unnecessary therapy.

Several randomized trials [14–17] have shown the safety of omitting radiotherapy, however, with little impact on clinical practice [18–20], because there are subgroups of fit older patients where radiotherapy cannot be systematically omitted [21–23]. The impact of local relapse on quality of life should be considered when radiotherapy is intended to omit [24, 25]. To overcome this problem and to prevent under-treatment, accelerated partial breast irradiation (APBI) can be considered an alternative to conventional external beam radiotherapy or exclusive hormonal therapy because it improves convenience for women with low-risk tumors [26–35]. Moreover, the side effects of hormonal therapy can modify the quality of life and patients’ reported outcomes during follow-up without a real benefit on overall survival [26–35].

The present systematic review was performed to assess the effectiveness and outcomes of APBI in the adjuvant treatment of elderly patients with breast cancer.

2. Materials and Methods

A systematic research using PubMed, Scopus, and Cochrane library was performed to identify full articles analyzing the efficacy of APBI in elderly patients with breast cancer. ClinicalTrials.gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. The studies were identified through the following medical subject headings (MeSH) and keywords including “breast cancer”, “brachyth-erapy”, “elderly”, and “palliation”. The search was restricted to the English language. The Medline search strategy was (“Brachytherapy” [Mesh] OR “Brachythe-rapy” [All Fields]) AND (“Breast Neoplasms” [Mesh] OR “Breast neoplasms” [All Fields] AND “Aged” [Mesh] OR “Aged” [All Fields]). To avoid missing relevant studies, we chose this strategy with high sensitivity but low specificity.

We analyzed only clinical full-text studies of elderly breast cancer patients treated with APBI alone. Conference papers, surveys, letters, editorials, book chapters, and reviews were excluded. Time restriction (1990–2018) as concerns the years of the publication was considered.

Two independent radiation oncologists expert in radiotherapy for breast cancer (VL expert in interventional radiotherapy and VM expert in external beam radiotherapy) screened citations in titles and abstracts to identify appropriate papers. Eligible citations were retrieved for full-text review. Uncertainties about their inclusion in the review were controlled by an expert multidisciplinary team composed by a radiation oncologist expert in interventional radiotherapy of another institution (GK), a surgeon (GG), a medical and radiation oncologist (FM), and a geriatrician (GC). Finally, an expert committee (VV, MAG, and LT) performed an independent check and the definitive approval of the review.

The primary outcome was the disease-free survival after APBI during follow-up. Secondary outcomes included specific cancer survival, overall survival, and adverse event rates.

A summary table (Table 1) was created including mono/multicentric study, sample size, median age, disease-free survival (DFS), toxicity, cancer-specific survival (CSS), and overall survival (OS).

3. Results

The literature search resulted in 420 articles (Figure 1). After the screening of the titles, abstracts, and language of these references, 378 studies were excluded, and 16 full-text articles were selected. Of these, 7 papers fulfilled the eligibility criteria.

Only one study is randomized [36], two studies are phase II [37, 38], and 4 studies are retrospective investigations [39–42]. Following the defined selection criteria, only data from the APBI treatments in elderly patients were extracted and considered for the analysis. The number of evaluated patients was 405 and the median age was 77.7 years. The DFS range was 96.1%–100%, the grade 3–4 toxicity range was 0%–6.6%, the CSS range was 97.9%–100%, and the OS range was 87%–100%.

Table 1 lists the characteristics of the included studies. All studies reported excellent/good cosmetic results in a range of 74% to 99%.

4. Discussion

Elderly breast cancer represents one of the main public health issues, which will become more critical with the increasing life expectancy. Patients aged 70 years and over who are in good health condition have a median life expectancy of 15.5 years and half of them will live much longer [43, 44].

Optimal treatment decisions should not be based on chronological age alone, but need to ensure that elderly patients get the best possible quality of care. The presence of other characteristics (concurrent comorbid illnesses) that represent potential causes of mortality must also be considered to identify those women who are unlikely to die of breast cancer and for whom the omission of adjuvant treatment may be the best option. A geriatric assessment should be mandatory because it provides specific and overall information about the health status, focusing on somatic, functional, and psychosocial domains, which is necessary to provide a multidisciplinary treatment plan [45].
Unfortunately, only a limited number of studies have focused on the role of geriatric assessment in treatment decisions for older early breast cancer patients [46]. It is well known that elderly women are undertreated with breast-conserving surgery (BCS) in favor of mastectomy [47, 48]. There are many reasons for this, such as logistical concerns.

| Author               | Period     | Study Type | Sample size, n | APBI | Median age, years | DFS Recurrent at 3 years: | Toxicity (G3-G4) | CSS Recurrent at 3 years: | OS Recurrent at 3 years: |
|----------------------|------------|------------|----------------|------|------------------|--------------------------|------------------|--------------------------|-------------------------|
| Cozzi et al. [39]    | 2006–17    | Retrospective | 86             | HDR-IRT | 82 (44–92)      | 96% Primary at 3 years: 97.8% Primary at 3 years: 97.6% at 5 years | 5.6%          | 100% at 3 years           | 100% at 3 years           |
| Genebes et al. [40]  | 2005–16    | Retrospective | 70             | HDR-IRT | 80.7 (62–93.1)  | 97.6% at 5 years          | 0%            | 97.9% at 5 years           | 93.2% at 5 years           |
| Hannoun-Lévi et al. [37] | 2012–14   | Phase II   | 26             | HDR-IRT | 77 (69–89)      | 100% at 3 years           | 0%            | 100% at 3 years           | 95.2% at 3 years           |
| Hannoun-Lévi et al. [38] | 2004–08   | Phase II   | 40             | HDR-IRT | 74 (70–87)      | 2%           | 100% at 3 years           | 100% at 3 years           |
| Kinj et al. [41]     | 2012–15    | Retrospective | 45             | HDR-IRT | 77.7 (65–92)    | 100%,                       | 6.6%          | 100% at 3 years           | 93.1% at 3 years           |
| Meattini et al. [36] | 2005–13    | Randomized phase 3 | 58 EBRT | IMRT | EBRT 74.1 (70.0–83.2) | 100% at 3 years           | 5.1%          | 100% at 5 years           | 5%                       |
| Sumodhee et al. [42] | 2005–16    | Retrospective | 79             | HDR-IRT | 77 (66–89)      | EBRT 96.1% at 5 years | APBI 98.1% at 5 years | 97.4% at 10 years | 98.1%                   |

APBI: accelerated partial breast irradiation; HDR-IRT: high dose rate interventional radiotherapy; IMRT: intensity-modulated radiotherapy; EBRT: external beam radiotherapy; DFS: disease-free survival; CSS: cancer specific survival; OS: overall survival.

Figure 1: PRISMA flowchart for the outcome and late adverse effects.
related to radiotherapy, the possibility of comorbidity, functional impairment, frailty, ideas about body-image, among others.

Furthermore, relatively few elderly patients are accrued in clinical trials. Barriers to the accrual of elders include “physician bias” based on the fear that the patient will not tolerate or will not benefit from the treatment and “patient and family members bias” based on the belief that treatment is not worthwhile or is too toxic. The treatment of elderly breast cancer patients often does not comply with guidelines and older women may receive less of adjuvant radiotherapy following BCS and variably more hormonal therapy. For this reason, for elderly patients with early breast cancer, the choice of the appropriate adjuvant treatment remains challenging.

Multiple trials over the years have investigated the role of RT and TAM in low-risk breast cancer patients in terms of local recurrence (LR), metastases disease-free survival (DMFS), and OS [49–53] and the possibility of avoiding RT [14–17]. Sole adjuvant endocrine or radiotherapy seems to be equivalent to all important oncological endpoints. Endocrine therapy is frequently associated with fatigue symptoms and possible severe side effects like thromboembolic events, endometrial cancer related to tamoxifen, as well as osteoporosis, cardiovascular disease, and arthralgia related to aromatase inhibitors. In contrast to radiotherapy at least 5 years lasting endocrine therapy, the typical side effects of a three-week hypofractionated adjuvant radiotherapy course, like low-grade erythemas and minor edemas, appear relatively moderated and are of short duration [54]. Moreover, it is important to keep in mind that personalized treatment decisions should be based on the patient’s baseline risk of recurrence. Indeed, there is strong evidence that the addition of radiotherapy reduces the risk of breast and axillary recurrence and this effect is maintained at 10 years, while radiotherapy does not significantly affect distant recurrence or overall survival rates in patients over 70 years old [14–17].

Moreover, it is important to consider the adherence of patients to endocrine therapy: given the associated adverse effects including hot flashes, thrombotic events, bone loss, and joint pain/stiffness, several studies reported a dropout of treatment adherence up to the rate of 67% in the first year of treatment, with a further reduction up to 30% in the fifth year [55, 56]. In the longer term, the potential effect of a local relapse on quality of life and the psychological state in older patients should not be underestimated.

An important issue to consider is that not all patients 70 or older are the same. A healthy 70-year-old woman has a high chance of living for more than 10 years, risking a one-in-10 rate of local recurrence if radiotherapy is omitted and a one-in-50 rate if radiotherapy is given. Conversely, in patients with significant comorbidities, the benefit of endocrine therapy can be questioned: the survival benefit of systemic treatment in patients with low-risk tumors is seen after 5 years, whereas the benefit of radiotherapy in reducing local recurrence is considerable in the first 5 years with a survival benefit at 15 years. In this subgroup of patients, perhaps endocrine therapy and not radiotherapy can be omitted.

The omission of radiotherapy may be proposed in low-risk breast cancer patients with limited life expectancy below 5 years. As most patients will present with substantially longer life expectancies, individual counseling about the risks and benefits of radiotherapy, based on clinical and biological features, is strongly recommended. Thus, there is no subgroup of fit older patients in whom post-BCS RT can be systematically omitted.

Since resistance to RT omission persists even in selected cases due to the risk of local recurrence and the availability of alternative forms of RT, APBI may consider a valuable compromise between EBRT and exclusive endocrine therapy.

Particularly in elderly patients, APBI presents many advantages like the possibility of delivering higher doses in the area of the tumor bed and in the same time reducing the dose to the normal breast tissue and adjacent organs at risk [57]. Additionally, a shorter treatment time might improve the convenience and quality of life of the patients, possibly reducing the physical and psychological stress related to radiotherapy [58–60]. These all increase their adherence and reduce the likelihood of inappropriate mastectomy [61–63]. Finally, APBI may reduce the total costs of treatment depending on the used modality [64]. There are many available techniques to perform APBI including intraoperative radiotherapy (IORT), three-dimensional or intensity-modulated EBRT involving stereotactic capabilities, or interventional radiotherapy (IRT). Careful patient selection is an important element to define which patients are suitable for APBI. Four published consensus statement criteria can help the radiation oncologist in this choice (ASTRO: American Society for Radiation Oncology; GEC-ESTRO: Groupe Européen de Curietherapie-European Society for Radiotherapy and Oncology; ABS: American Brachytherapy Society; ASBS: American Society of Breast Surgeons) [26–29]. Four phase III randomized trials on APBI have been published up to date, but none of these was specifically designed for older women [30, 31, 33, 34], and no comparison can be made with other trials in which the omission of radiation therapy has been investigated [15].

The 7 studies reported in this review showed excellent rates of DFS (range 96%–100%), CSS (97.9%–100%), and OS (87%–100%) with acceptable G3 toxicities (range 0%–6.6%). Moreover, all studies reported an excellent/good cosmetic result range 74%–99%.

Personalized assessments of the risk benefits are essential when considering older patients for adjuvant treatment after breast-conserving surgery. The use of large databases and nomogram could help for improved analysis of the outcomes in these populations [65–69].

5. Conclusions

APBI results in a safe and effective substitute for the adjuvant EBRT in selected elderly early-stage breast cancer patients. It is more convenient for high-volume radiation centers with long waiting lists and for patients who live far away from RT centers. Radiotherapy departments have to be aware of this issue, to provide the best therapeutic option combining
optimal local control with good quality of life in a cost-effective way. The actual choice of APBI techniques will be influenced by many factors whereby the strongest arguments are local experience and hospital budget size.

However, one of the most important considerations is to select the most appropriate patient population for this treatment strategy and this should be performed in experienced and trained hands.

In aged or frail patients, a comprehensive assessment of the overall health status is recommended when weighing the expected absolute benefits of cancer treatment against tumor biology, potential toxicities, physiological age, patient preference, quality of life, and remaining life expectancy.

Based on the relatively low toxicity, APBI should be advised in selected patients with life expectancies larger than 5–10 years.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012.

[2] S. G. Mohile and A. Magnuson, “Comprehensive geriatric assessment in oncology,” Cancer and Aging, vol. 38, pp. 85–103, 2013.

[3] L. P. Fried, C. M. Tangen, J. Walston et al., “Frailty in older adults: evidence for a phenotype,” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 56, pp. 146–156, 2001.

[4] A. Hurria, M. S. Lachs, H. J. Cohen, H. B. Muss, and A. B. Kornblith, “Geriatric assessment for oncologists: rationale and future directions,” Critical Reviews in Oncology/Hematology, vol. 59, no. 3, pp. 211–217, 2006.

[5] A. G. Pallis, C. Fortpied, U. Wedding et al., “EORTC elderly task force position paper: approach to the older cancer patient,” European Journal of Cancer, vol. 46, no. 9, pp. 1502–1513, 2010.

[6] L. Decoster, K. Van Puyvelde, S. Mohile et al., “Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations,” Annals of Oncology, vol. 26, no. 2, pp. 288–300, 2015.

[7] S. G. Mohile, W. Dale, M. R. Somerfield et al., “Practical assessment and Management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology,” Journal of Clinical Oncology, vol. 36, no. 22, pp. 2326–2347, 2018.

[8] V. Lancellotta, G. Kovács, L. Tagliaferri et al., “The role of personalized Intervventional Radiotherapy (brachytherapy) in the management of older patients with non-melanoma skin cancer,” Journal of Geriatric Oncology, vol. 10, no. 3, pp. 514–517, 2019.

[9] V. Lancellotta, G. Kovács, L. Tagliaferri et al., “Age is not a limiting factor in interventional radiotherapy (brachytherapy) for patients with localized cancer,” BioMed Research International, vol. 2018, Article ID 2178469, 10 pages, 2018.

[10] G. Kovács, L. Tagliaferri, and V. Valentini, “Is an interventional oncology center an advantage in the service of cancer patients or in the education? the gemelli hospital and Interacts experience,” Journal of Contemporary Brachytherapy, vol. 9, no. 6, pp. 497–498, 2017.

[11] C. Aristei, V. Lancellotta, M. Piergentini et al., “Individualized 3D-printed templates for high-dose-rate interstitial multi-cathether brachytherapy in patients with breast cancer,” Brachytherapy, vol. 18, no. 1, pp. 57–62, 2019.

[12] L. Tagliaferri, M. M. Pagliara, C. Masciocchi et al., “Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma,” Journal of Contemporary Brachytherapy, vol. 9, no. 6, pp. 540–547, 2017.

[13] J. M. Albert, D. D. Liu, Y. Shen et al., “Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery,” Journal of Clinical Oncology, vol. 30, no. 23, pp. 2837–2843, 2012.

[14] I. H. Kunkler, L. I. Williams, W. J. L. Jack, D. A. Cameron, and J. M. Dixon, “Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial,” The Lancet Oncology, vol. 16, no. 3, pp. 266–273, 2015.

[15] K. S. Hughes, L. A. Schnaper, D. Berry et al., “Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer,” New England Journal of Medicine, vol. 351, no. 10, pp. 971–977, 2004.

[16] A. W. Fyles, D. R. McCready, L. A. Manchul et al., “Tamoxifen with or without radiation in women 50 years of age or older with early breast cancer,” New England Journal of Medicine, vol. 351, no. 10, pp. 963–970, 2004.

[17] B. Fisher, J. Bryant, J. J. Dignam et al., “Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less,” Journal of Clinical Oncology, vol. 20, no. 20, pp. 4141–4149, 2002.

[18] C. Tinterrri, W. Gatzemeier, V. Zanini et al., “Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: a prospective randomised multicentre trial,” The Breast, vol. 18, no. 6, pp. 373–377, 2009.

[19] R. Pötter, M. Gnant, W. Kwasny et al., “Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer,” International Journal of Radiation Oncology•Biology•Physics, vol. 68, no. 2, pp. 334–340, 2007.

[20] P. R. Soulsou, J. B. Yu, K. B. Roberts et al., “Assessing the impact of a cooperative group trial on breast cancer care in the medicare population,” Journal of Clinical Oncology, vol. 30, no. 14, pp. 1601–1607, 2012.

[21] J. R. Bellon, E. E. R. Harris, D. W. Arthur et al., “ACR Appropriateness criteria conservative surgery and radiation-stage I and II breast carcinoma,” The Breast Journal, vol. 17, no. 5, pp. 448–455, 2011.

[22] A. Hurria, I. S. Browner, H. J. Cohen et al., “Senior adult oncology,” Journal of the National Comprehensive Cancer Network, vol. 10, no. 2, pp. 162–209, 2012.

[23] L. Biganzoli, H. Wildiers, C. Oakman et al., “Management of elderly patients with breast cancer: updated recommendations of the international society of geriatric oncology (SIOG) and European society of breast cancer specialists (EUSOMA),” Lancet Oncol, vol. 13, pp. 148–160, 2012.

[24] E. Perrucci, V. Lancellotta, V. Bini et al., “Quality of life and cosmesis after breast cancer: whole breast radiotherapy vs partial breast high-dose-rate brachytherapy,” Tumori Journal, vol. 101, no. 2, pp. 161–167, 2015.

[25] R. Schäfer, V. Strnad, C. Polgár et al., “Quality-of-life results for accelerated partial breast irradiation with interstitial
brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial,” The Lancet Oncology, vol. 19, no. 6, pp. 834–844, 2018.

[26] Z. A. Hussain, U. Mahmood, A. Hanlon et al., “Accelerated partial breast irradiation via brachytherapy: a patterns-of-care analysis with ASTRO consensus statement groupings,” Brachytherapy, vol. 10, no. 6, pp. 479–485, 2011.

[27] C. Polgár, E. V. Limbergen, R. Pöttker et al., “Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009),” Radiotherapy and Oncology, vol. 94, no. 3, pp. 264–273, 2010.

[28] C. Shah, F. Vicini, D. E. Wazer, D. Arthur, and R. R. Patel, “The American Brachytherapy Society consensus statement for accelerated partial breast irradiation,” Brachytherapy, vol. 12, no. 4, pp. 267–277, 2013.

[29] C. Correa, E. E. Harris, M. C. Leonardi et al., “Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement,” Practical Radiation Oncology, vol. 7, no. 2, pp. 73–79, 2017.

[30] V. Strnad, O. J. Ott, G. Hildebrandt et al., “5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial,” The Lancet, vol. 387, no. 10015, pp. 229–238, 2016.

[31] L. Livi, F. B. Buonamici, G. Simontacchi et al., “Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomised clinical trial,” International Journal of Radiation Oncology*Biology*Physics, vol. 77, no. 2, pp. 509–515, 2010.

[32] I. A. Olivotto, T. J. Whelan, S. Parpia et al., “Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy,” Journal of Clinical Oncology, vol. 31, no. 32, pp. 4038–4045, 2013.

[33] J. S. Vaidya, D. J. Joseph, J. S. Tobias et al., “Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial,” The Lancet, vol. 376, no. 9735, pp. 91–102, 2010.

[34] U. Veronesi, R. Orecchia, P. Maisonneuve et al., “Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial,” The Lancet Oncology, vol. 14, no. 13, pp. 1269–1277, 2013.

[35] C. Aristei, E. Maranzano, V. Lancirolla et al., “Partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy. Long-term results of a phase II prospective study,” Radiotherapy and Oncology, vol. 124, no. 2, pp. 208–213, 2017.

[36] I. Meattini, C. Saieva, L. Marrazzo et al., “Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial,” Breast Cancer Research and Treatment, vol. 153, no. 3, pp. 539–547, 2015.

[37] J.-M. Hannoun-Lévi, D. L. Cham Kee, J. Gal et al., “Accelerated partial breast irradiation for suitable elderly women using a single fraction of multicatheter interstitial high-dose-rate brachytherapy: early results of the Single-Fraction Elderly Breast Irradiation (SiFEBI) Phase I/II trial,” Brachytherapy, vol. 17, no. 2, pp. 407–414, 2018.
[51] R. Gennari, G. Curigliano, N. Rotmensz et al., "Breast carcinoma in elderly women," *Cancer*, vol. 101, no. 6, pp. 1302–1310, 2004.

[52] S. G. Diab, R. M. Elledge, and G. M. Clark, "Tumor characteristics and clinical outcome of elderly women with breast cancer," *Journal of the National Cancer Institute*, vol. 92, pp. 550–556, 2001.

[53] K.-J. Winzer, W. Sauerbrei, M. Braun et al., "Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2×2 randomised clinical trial in patients with low risk of recurrence," *European Journal of Cancer*, vol. 46, no. 1, pp. 95–101, 2010.

[54] S. F. Shaitelman, A. J. Khan, W. A. Woodward et al., "Shortened radiation therapy schedules for early-stage breast cancer: a review of hypofractionated whole-breast irradiation and accelerated partial breast irradiation," *The Breast Journal*, vol. 20, no. 2, pp. 131–146, 2014.

[55] H. Zhao, N. Hei, Y. Wu et al., "Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ," *Cancer*, vol. 123, no. 6, pp. 940–947, 2017.

[56] R. T. Chlebowski, J. Kim, and R. Haque, "Adherence to endocrine therapy in breast cancer adjuvant and prevention settings," *Cancer Prevention Research*, vol. 7, no. 4, pp. 378–387, 2014.

[57] M. Mukesh, E. Harris, R. Jena, P. Evans, and C. Coles, "Relationship between irradiated breast volume and late normal tissue complications: a systematic review," *Radiotherapy and Oncology*, vol. 104, no. 1, pp. 1–10, 2012.

[58] L. Tagliaferri, V. Lancellotta, T. Zinicola et al., "Cosmetic assessment in brachytherapy (interventional radiotherapy) for breast cancer: a multidisciplinary review," *Brachytherapy*, vol. 18, 2019.

[59] L. Tagliaferri, C. Soatti, P. G. Kovacs, and C. Aristei, "A national survey of AIRO (Italian Association of Radiation Oncology) brachytherapy (Interventional Radiotherapy) study group," *Journal of Contemporary Brachytherapy*, vol. 10, pp. 254–259, 2018.

[60] L. Tagliaferri, G. Kovacs, C. Aristei et al., "Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey," *Journal of Contemporary Brachytherapy*, vol. 11, pp. 48–53, 2018.

[61] L. Tagliaferri, G. Kovács, R. Autorino et al., "ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy)," *Journal of Contemporary Brachytherapy*, vol. 4, pp. 336–343, 2016.

[62] S. G. Diab, R. M. Elledge, and G. M. Clark, "Tumor characteristics and clinical outcome of elderly women with breast cancer," *Journal of the National Cancer Institute*, vol. 92, pp. 550–556, 2001.

[63] K.-J. Winzer, W. Sauerbrei, M. Braun et al., "Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2×2 randomised clinical trial in patients with low risk of recurrence," *European Journal of Cancer*, vol. 46, no. 1, pp. 95–101, 2010.

[64] S. F. Shaitelman, A. J. Khan, W. A. Woodward et al., "Shortened radiation therapy schedules for early-stage breast cancer: a review of hypofractionated whole-breast irradiation and accelerated partial breast irradiation," *The Breast Journal*, vol. 20, no. 2, pp. 131–146, 2014.

[65] H. Zhao, N. Hei, Y. Wu et al., "Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ," *Cancer*, vol. 123, no. 6, pp. 940–947, 2017.

[66] R. T. Chlebowski, J. Kim, and R. Haque, "Adherence to endocrine therapy in breast cancer adjuvant and prevention settings," *Cancer Prevention Research*, vol. 7, no. 4, pp. 378–387, 2014.

[67] M. Mukesh, E. Harris, R. Jena, P. Evans, and C. Coles, "Relationship between irradiated breast volume and late normal tissue complications: a systematic review," *Radiotherapy and Oncology*, vol. 104, no. 1, pp. 1–10, 2012.

[68] L. Tagliaferri, V. Lancellotta, T. Zinicola et al., "Cosmetic assessment in brachytherapy (interventional radiotherapy) for breast cancer: a multidisciplinary review," *Brachytherapy*, vol. 18, 2019.

[69] L. Tagliaferri, C. Soatti, P. G. Kovacs, and C. Aristei, "A national survey of AIRO (Italian Association of Radiation Oncology) brachytherapy (Interventional Radiotherapy) study group," *Journal of Contemporary Brachytherapy*, vol. 10, pp. 254–259, 2018.

[70] L. Tagliaferri, G. Kovacs, R. Autorino et al., "ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy)," *Journal of Contemporary Brachytherapy*, vol. 4, pp. 336–343, 2016.

[71] S. G. Diab, R. M. Elledge, and G. M. Clark, "Tumor characteristics and clinical outcome of elderly women with breast cancer," *Journal of the National Cancer Institute*, vol. 92, pp. 550–556, 2001.

[72] K.-J. Winzer, W. Sauerbrei, M. Braun et al., "Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2×2 randomised clinical trial in patients with low risk of recurrence," *European Journal of Cancer*, vol. 46, no. 1, pp. 95–101, 2010.

[73] S. F. Shaitelman, A. J. Khan, W. A. Woodward et al., "Shortened radiation therapy schedules for early-stage breast cancer: a review of hypofractionated whole-breast irradiation and accelerated partial breast irradiation," *The Breast Journal*, vol. 20, no. 2, pp. 131–146, 2014.

[74] H. Zhao, N. Hei, Y. Wu et al., "Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ," *Cancer*, vol. 123, no. 6, pp. 940–947, 2017.

[75] R. T. Chlebowski, J. Kim, and R. Haque, "Adherence to endocrine therapy in breast cancer adjuvant and prevention settings," *Cancer Prevention Research*, vol. 7, no. 4, pp. 378–387, 2014.

[76] M. Mukesh, E. Harris, R. Jena, P. Evans, and C. Coles, "Relationship between irradiated breast volume and late normal tissue complications: a systematic review," *Radiotherapy and Oncology*, vol. 104, no. 1, pp. 1–10, 2012.

[77] L. Tagliaferri, V. Lancellotta, T. Zinicola et al., "Cosmetic assessment in brachytherapy (interventional radiotherapy) for breast cancer: a multidisciplinary review," *Brachytherapy*, vol. 18, 2019.

[78] K. Albuquerque, D. Tell, P. Lobo, L. Millbrandt, H. L. Mathews, and L. W. Janusek, "Impact of partial versus whole breast radiation therapy on fatigue, perceived stress, quality of life and natural killer cell activity in women with breast cancer," *BMC Cancer*, vol. 12, p. 251, 2012.

[79] E. Kawase, K. Karasawa, S. Shimotsu et al., "Estimation of anxiety and depression in patients with early stage breast cancer before and after radiation therapy," *Breast Cancer*, vol. 19, no. 2, pp. 147–152, 2012.

[80] D. C. Farrow, W. C. Hunt, and J. M. Samet, "Geographic variation in the treatment of localized breast cancer," *New England Journal of Medicine*, vol. 326, pp. 1097–1101, 1992.

[81] R. Autorino, L. Vicenzi, V. Tagliaferri, C. Soatti, P. G. Kovacs, and C. Aristei, "A national survey of AIRO (Italian Association of Radiation Oncology) brachytherapy (Interventional Radiotherapy) study group," *Journal of Contemporary Brachytherapy*, vol. 10, pp. 254–259, 2018.

[82] L. Tagliaferri, G. Kovács, C. Aristei et al., "Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey," *Journal of Contemporary Brachytherapy*, vol. 11, pp. 48–53, 2018.

[83] W. W. Suh, L. J. Pierce, F. A. Vicini, and J. A. Hayman, "A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer," *International Journal of Radiation Oncology*Biology*Physics*, vol. 62, no. 3, pp. 790–796, 2005.

[84] L. Tagliaferri, C. Gobitti, G. F. Colloca et al., "A new standardized data collection system for interdisciplinary thyroid cancer management: thyroid COBRA," *European Journal of Internal Medicine*, vol. 53, pp. 73–78, 2018.